- Home
- S vs TVTX Comparison
S vs TVTX Comparison
Compare S & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | S | TVTX |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.3B |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | S | TVTX |
|---|---|---|
| Price | $17.78 | $56.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 31 | 13 |
| Target Price | $19.28 | ★ $40.62 |
| AVG Volume (30 Days) | ★ 6.0M | 2.1M |
| Earning Date | 05-27-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,001,278,000.00 | N/A |
| Revenue This Year | $22.84 | $44.76 |
| Revenue Next Year | $17.32 | $35.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 21.89 | N/A |
| 52 Week Low | $11.81 | $15.03 |
| 52 Week High | $21.40 | $60.10 |
Technical Indicators
Market Signals| Indicator | S | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 59.45 | 60.20 |
| Support Level | $14.09 | $54.87 |
| Resistance Level | $18.81 | $60.10 |
| Average True Range (ATR) | 0.93 | 2.13 |
| MACD | 0.27 | -0.39 |
| Stochastic Oscillator | 72.98 | 39.36 |
Price Performance
Historical ComparisonAbout S SentinelOne Inc.
SentinelOne is a cloud-based cybersecurity company specializing in endpoint protection. SentinelOne's primary offering is its Singularity platform that offers a single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The California-based firm was founded in 2013 and went public in 2021.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.